NASDAQ:ACIU AC Immune (ACIU) Stock Price, News & Analysis $3.21 +0.02 (+0.63%) (As of 10/17/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About AC Immune Stock (NASDAQ:ACIU) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AC Immune alerts:Sign Up Key Stats Today's Range$3.18▼$3.2250-Day Range$2.99▼$3.7852-Week Range$2.20▼$5.14Volume54,196 shsAverage Volume366,357 shsMarket Capitalization$317.47 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingBuy Company OverviewAC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Read More… Here’s how to start a “Weekend Side Hustle” from your sofa (Ad)Here’s how you can start your very own “Weekend Side Hustle” right from the comfort of your sofa! It doesn't matter if you have a multi-million dollar retirement account… Or if you’re just starting out with a few thousand. And that’s how you can kickstart your very own “Weekend Side Hustle!” Now that you know that…Let me show you how I target extra income as early as THIS weekend! AC Immune Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks47th Percentile Overall ScoreACIU MarketRank™: AC Immune scored higher than 47% of companies evaluated by MarketBeat, and ranked 679th out of 1,013 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAC Immune has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAC Immune has only been the subject of 1 research reports in the past 90 days.Read more about AC Immune's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for AC Immune are expected to grow in the coming year, from ($0.89) to $0.01 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AC Immune is -4.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AC Immune is -4.46, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAC Immune has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about AC Immune's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.39% of the float of AC Immune has been sold short.Short Interest Ratio / Days to CoverAC Immune has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in AC Immune has recently increased by 12.92%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAC Immune does not currently pay a dividend.Dividend GrowthAC Immune does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.39% of the float of AC Immune has been sold short.Short Interest Ratio / Days to CoverAC Immune has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in AC Immune has recently increased by 12.92%, indicating that investor sentiment is decreasing significantly. News and Social Media2.8 / 5News Sentiment0.98 News SentimentAC Immune has a news sentiment score of 0.98. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for AC Immune this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ACIU on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AC Immune insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.60% of the stock of AC Immune is held by insiders.Percentage Held by Institutions51.36% of the stock of AC Immune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AC Immune's insider trading history. Receive ACIU Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AC Immune and its competitors with MarketBeat's FREE daily newsletter. Email Address ACIU Stock News HeadlinesAC Immune SA (NASDAQ:ACIU) Sees Significant Growth in Short InterestOctober 16 at 3:01 AM | americanbankingnews.comAnalyzing AC Immune (NASDAQ:ACIU) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT)October 11, 2024 | americanbankingnews.comThis man predicted today’s most valuable companies more than a decade ago.How could it be that one analyst called the rise of Apple, Microsoft, Nvidia, and many of today’s best performing stocks more than a decade ago? Some might say it was luck… Others will say he was in the right place at the right time. But looking back, this analyst has made some incredible calls over his career… In fact, right now, he’s the #1 ranked stock picker in North America… To earn that title he’s beat out more than 16,000 stock market professionals. So how does one man accomplish all that? If you were to ask him, he’d give the credit to his stock rating system…. A system that has a history of predicting which stocks could soon rise by 100% or more…October 18, 2024 | DTI (Ad)Buy Rating Justified: AC Immune SA’s Strategic Advancements in Alzheimer’s Treatment and Strong Financial PositionSeptember 18, 2024 | markets.businessinsider.comAnalyst Issues Buy Rating for AC Immune SA on Promising Alzheimer’s Treatment ProspectsSeptember 18, 2024 | markets.businessinsider.comAC Immune SA: AC Immune Receives Second Milestone Payment Following Progress in Phase 2b ReTain Trial of ACI-35.030 in Preclinical Alzheimer's DiseaseSeptember 17, 2024 | finanznachrichten.deAC Immune Gets FDA Fast-Track Designation for Neurodegenerative Diagnostic ScanAugust 29, 2024 | marketwatch.comAC Immune’s PI-2620 Tau-PET Diagnostic in Phase 3 Receives Fast Track Designation in Three Neurodegenerative ConditionsAugust 29, 2024 | markets.businessinsider.comSee More Headlines ACIU Stock Analysis - Frequently Asked Questions How have ACIU shares performed this year? AC Immune's stock was trading at $5.00 at the start of the year. Since then, ACIU shares have decreased by 35.8% and is now trading at $3.21. View the best growth stocks for 2024 here. How were AC Immune's earnings last quarter? AC Immune SA (NASDAQ:ACIU) posted its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.25) earnings per share for the quarter, missing analysts' consensus estimates of $0.42 by $0.67. The firm had revenue of $0.76 million for the quarter, compared to analyst estimates of $91.60 million. When did AC Immune IPO? AC Immune (ACIU) raised $55 million in an initial public offering on Friday, September 23rd 2016. The company issued 4,600,000 shares at $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO. How do I buy shares of AC Immune? Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of AC Immune own? Based on aggregate information from My MarketBeat watchlists, some other companies that AC Immune investors own include Meta Platforms (META), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Tesla (TSLA), Advanced Micro Devices (AMD) and Canopy Growth (CGC). Company Calendar Last Earnings8/06/2024Today10/17/2024Next Earnings (Estimated)11/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ACIU CUSIPN/A CIK1651625 Webwww.acimmune.com Phone(121) 345-9121Fax41-21-345-9120Employees140Year FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$16.00 Low Stock Price Target$8.00 Potential Upside/Downside+273.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.69) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-60,410,000.00 Net MarginsN/A Pretax Margin-391.24% Return on Equity-43.72% Return on Assets-33.24% Debt Debt-to-Equity RatioN/A Current Ratio1.80 Quick Ratio1.80 Sales & Book Value Annual Sales$15.49 million Price / Sales20.50 Cash FlowN/A Price / Cash FlowN/A Book Value$2.12 per share Price / Book1.51Miscellaneous Outstanding Shares98,899,000Free Float94,389,000Market Cap$317.47 million OptionableOptionable Beta1.25 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:ACIU) was last updated on 10/18/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredAdd $2T of Potential Magic to Your PortfolioRevolutionizing a whole $2T entertainment and licensing industry might sound like the stuff of fairytales. But...Elf Labs | SponsoredEquation for Profits: Volatility = OpportunityFREE Intro to Options Class Online Tonight Prosper Trading Academy | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredA Totally New ‘Income Coin’Buckle up… Because this might shatter everything you thought you knew about "income trading." In fact, i...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AC Immune SA Please log in to your account or sign up in order to add this asset to your watchlist. Share AC Immune With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.